CiplaCPLFY 94 OCF Yield % is 3.60 as of Jun. 27, 2026. GuruFocus rates CPLFY with a GF Score™ of 94/100. The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Cipla ranks worse than 50.15% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Cipla OCF Yield % Related Terms
Cipla OCF Yield % Historical Data
* Premium members only.
The historical data trend for Cipla's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Cipla's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipla (CPLFY) has a OCF Yield % of 3.60 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cipla and its competitors. Over the past decade, Cipla's OCF Yield % has ranged from 3.60 to 3.60. According to the industry distribution chart, Cipla ranks #504 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 50.1%.
Is Cipla's OCF Yield % too high?
Cipla's current OCF Yield % is 3.60. Over the past 10 years, this metric has ranged from a low of 3.60 to a high of 3.60. The Drug Manufacturers industry median OCF Yield % is 3.61. Cipla's value of 3.60 is 0.3% below this industry median. Based on the distribution chart, Cipla ranks #504 out of 1005 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's OCF Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #504 out of 1005 companies for OCF Yield %. This places Cipla in the lower half of its industry. The industry median OCF Yield % is 3.61. Cipla's value of 3.60 is 0.3% below this benchmark. Historically, Cipla's own OCF Yield % has ranged from 3.60 to 3.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current OCF Yield % of 3.60 is 0.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current OCF Yield % is 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (CPLFY) has a current OCF Yield % of 3.60. The current OCF Yield % is 3.60 and 0.3% below the Drug Manufacturers industry median of 3.61. Cipla's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Cipla (CPLFY), the current OCF Yield % is 3.60 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPLFY has been successfully added to your 